Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-11-30 DOI:10.1080/2162402x.2023.2286820

Hélène Poinot, Eloïse Dupuychaffray, Grégoire Arnoux, Montserrat Alvarez, Jérémie Tachet, Ounss Ezzar, Jonathan Moore, Olivia Bejuy, Eulalia Olesti, Gioele Visconti, Víctor González-Ruiz, Serge Rudaz, Jean-Christophe Tille, Clarissa D. Voegel, Patrycja Nowak-Sliwinska, Carole Bourquin, Aurélien Pommier

引用次数: 0

Abstract

Although immune-based therapies have revolutionized the management of cancer, novel approaches are urgently needed to improve their outcome. We investigated the role of endogenous steroids in the r...

查看原文本刊更多论文

HSD11B1激活内源性糖皮质激素抑制肾癌的抗肿瘤免疫反应

尽管基于免疫的治疗已经彻底改变了癌症的管理，但迫切需要新的方法来改善其结果。我们研究了内源性类固醇在r…

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.